Literature DB >> 22778830

ACS chemical neuroscience molecule spotlight on savella.

Corey R Hopkins1.   

Abstract

Savella (milnacipran), a selective serotonin and noradrenaline reuptake inhibitor, was approved by the FDA on January 14th, 2009, for the treatment of fibromyalgia.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 22778830      PMCID： PMC3368674          DOI： 10.1021/cn1000233

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  3 in total

1.  Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug.

Authors:  C Moret; M Charveron; J P Finberg; J P Couzinier; M Briley
Journal:  Neuropharmacology       Date:  1985-12       Impact factor: 5.250

2.  Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.

Authors:  Daniel J Clauw; Philip Mease; Robert H Palmer; R Michael Gendreau; Yong Wang
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

3.  The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Authors:  Philip J Mease; Daniel J Clauw; R Michael Gendreau; Srinivas G Rao; Jay Kranzler; Wei Chen; Robert H Palmer
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.